Tocilizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tocilizumab and local guidelines before prescribing.
Mechanism
Interleukin-6 receptor antagonist.
Uses
Rheumatoid arthritis, giant cell arteritis, COVID-19 (selected), cytokine release syndrome.
Dosing
- Hospital patients needing oxygen: Dexamethasone (6 mg daily for up to 10 days) and, in selected patients, an IL-6 inhibitor (tocilizumab). VTE prophylaxis.
Respiratory: Infections - Hospitalised patients needing oxygen - dexamethasone 6 mg daily for up to 10 days ; tocilizumab or baricitinib in severe disease (specialist); VTE prophylaxis; prone positioning and respiratory support.
ID: Viral, fungal and parasitic infections - 3. A patient with rheumatoid arthritis on tocilizumab has fever and confusion. CRP is 6 mg/L. Answer: Possible sepsis masked by IL-6 blockade.
Clinical Immunology: Immune system basics and immunological investigations
Side effects
Infections, raised LFT and lipids, neutropenia, gastrointestinal perforation.
Interactions
Live vaccines contraindicated; CYP-substrate drug levels may fall.
Contraindications and cautions
Active infection, neutropenia
Monitoring
TB screen, FBC, LFT, lipids
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Caution in liver disease
Overdose and reversal
Supportive
Special advice
Screen for TB; monitor FBC and LFT; may blunt CRP and fever in infection.
More from the textbook: uses, cautions and other points
- Treatment: Mycophenolate (or cyclophosphamide); tocilizumab or rituximab in selected cases; nintedanib for progression.
Respiratory: Interstitial Lung Disease - Tocilizumab for relapsing or refractory disease (NICE TA518).
Neurology: Emergencies - Blinatumomab and other bispecific antibodies; CAR-T cells | ALL, lymphoma, myeloma | Cytokine release syndrome (fever, low BP - tocilizumab), neurotoxicity (ICANS), infections, low antibodies
Haematology: Anatomy Physiology and Pharmacology - Cytokine release syndrome - fever, low BP, hypoxia. Treated with tocilizumab and steroids.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Tocilizumab | Cytokine release syndrome after CAR-T.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - CAR-T cells / bispecific antibodies | Relapsed lymphoma and myeloma; cytokine release syndrome (tocilizumab) and neurotoxicity (ICANS, dexamethasone); infection and hypogammaglobulinaemia.
Haematology: Myeloma and Lymphoma
Where it is discussed in the book
- Respiratory: Infections (1 mention)
- Respiratory: Interstitial Lung Disease (1 mention)
- Neurology: Emergencies (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (2 mentions)
- Haematology: Myeloma and Lymphoma (1 mention)
- Oncology: Emergencies (1 mention)
- Paediatrics: Neurology, bones and joints in children (2 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (5 mentions)
- Rheumatology: Connective tissue diseases (1 mention)
- Rheumatology: Inflammatory arthritis (1 mention)
- Rheumatology: Vasculitis, GCA and PMR (7 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (6 mentions)
- Ophthalmology: Retinal Visual Loss (3 mentions)
- Ophthalmology: Neuro-ophthalmology (1 mention)
- ID: Viral, fungal and parasitic infections (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (8 mentions)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (10 mentions)
- Integrated respiratory chapter (2 mentions)
- Integrated paediatrics chapter (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)